CARCINOMA, HEPATOCELLULAR

This study tested whether adding a third drug (relatlimab) to a standard two-drug treatment (nivolumab and bevacizumab) is safe and works better for people with advanced liver cancer who haven't had treatment before. 83 adults with advanced liver cancer took part. The goal was to…

This study tested different combinations of immunotherapy drugs given before surgery to people with liver cancer that could be removed. The goal was to see if these treatments could shrink the tumor or eliminate it entirely before the operation. 62 participants took part, and the…

This study tested a new drug (E7386) combined with an immunotherapy (pembrolizumab) in 89 people with advanced melanoma, colorectal, or liver cancer who had already tried other treatments. The goal was to check safety and see if the combination shrinks tumors. Results help decide…

This study tested a radioactive oil called Lipiocis given directly into the liver's blood supply. The goal was to see if it could prevent liver cancer from returning in 73 patients with cirrhosis who had already had their tumors removed or destroyed. The treatment aims to reduce …

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer procedure called TACE helps people with liver cancer that cannot be cured but hasn't spread. About 479 adults took part. The goal was to see if the combination slows cancer growth…

This study tested whether adding the immunotherapy drug pembrolizumab to the targeted therapy lenvatinib helps people with advanced liver cancer live longer or delay tumor growth. About 794 adults with advanced liver cancer that could not be treated with surgery or local therapie…

This study tested whether adding the immunotherapy drug pembrolizumab to standard supportive care helps Asian patients with advanced liver cancer live longer. The trial enrolled 453 patients who had already received one prior treatment. Results showed that pembrolizumab extended …

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 152 people with advanced liver cancer that could not be removed by surgery and had not been treated with systemic therapy before. The main goal was to check safety, especially serious bleeding side eff…

This study looked at whether a new biomarker called 'mass response' can help predict how well cancer treatments will work. Researchers collected tumor cells from 72 adults with various cancers using fluid samples or biopsies. The goal was to see if this biomarker could guide ther…

This study tested 892 African and Asian immigrants in Minnesota for hepatitis B and C to understand how common these infections are and how they increase the risk of liver cancer. Researchers also looked at viral genetics and immune responses. No treatment was given; the goal was…